Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
252 stopped studies mapped to Malignant Gastric Neoplasm and descendants · 88% state a reason
Over the 252 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | Genmab | Sponsor decision | Sponsor / business decision |
| NCT04591028 | A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in… | Phase 4 | withdrawn | Oct 19, 2020 | Mayo Clinic | Lack of funding. | Funding |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell… | Phase 2 | withdrawn | Jun 9, 2022 | Ellipses Pharma | Futility analysis decision to terminate EP0057 compound and all Ellipses sponsored studies… | Efficacy / futility |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating… | Phase 1 / Phase 2 | withdrawn | Jan 26, 2015 | Eastern Cooperative Oncology Group | The study did not open to accrual. No start date and no completion dates. | Enrollment / accrual |
| NCT02489214 | Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer | Phase 1 / Phase 2 | terminated | Jul 2, 2015 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Corporate policy adjustments | Other (stated, no rule matched) |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects… | Phase 1 | suspended | Dec 2, 2020 | Bellicum Pharmaceuticals | Due to a Dose Limiting Toxicity in another sister trial with same technology. | Safety / toxicity |
| NCT04510285 | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+… | Phase 2 | terminated | Aug 12, 2020 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal… | N/A | terminated | Sep 4, 2019 | Stanford University | Covid-19 | COVID-19 / pandemic |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT04168931 | Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC(GASTHER2) | Phase 2 | terminated | Nov 19, 2019 | AC Camargo Cancer Center | recruitment failure | Enrollment / accrual |
| NCT04868747 | The Effect of Perioperative Lidocaine Infusion on Neutrophil Extracellular Trapping | N/A | withdrawn | May 3, 2021 | The Catholic University of Korea | due to financial problem | Funding |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT02191566 | S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy(SOHUG) | Phase 2 | terminated | Jul 16, 2014 | Kangbuk Samsung Hospital | The patient's study enrollment was too low. | Enrollment / accrual |
| NCT05431244 | Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in… | N/A | withdrawn | Jun 24, 2022 | Samsung Medical Center | Research withdrawal before patient registration due to difficulty in continuing research | Other (stated, no rule matched) |
| NCT01665274 | Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer(repeat) | Phase 2 | terminated | Aug 15, 2012 | Harbin Medical University | we are working on a larger similar multicenter cinical trials as a participant.so in order to avoid… | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies… | Phase 1 / Phase 2 | terminated | Oct 25, 2021 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on… | Phase 1 / Phase 2 | terminated | Apr 2, 2014 | Polaris Group | not stated | Not stated |
| NCT03721042 | Demonstrating the Diagnostic Power of an Electronic Nose: Study on Exhaled Air Samples(OLFADIAG) | N/A | terminated | Oct 26, 2018 | Nouvelle Clinique Bonnefon | no PI to continue the study | Other (stated, no rule matched) |
| NCT03707028 | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With… | Phase 1 / Phase 2 | terminated | Oct 16, 2018 | Elevar Therapeutics | Terminated after completion of Part 1 due to a change in research plan. | Other (stated, no rule matched) |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases… | Phase 1 | withdrawn | Sep 25, 2018 | Sorrento Therapeutics, Inc. | Unable to enroll subjects | Enrollment / accrual |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's… | Phase 1 / Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | Per PI Request | Other (stated, no rule matched) |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors…(ILIAD) | Phase 1 | terminated | Nov 8, 2018 | Mendus | Decision made not to move to Phase 2 | Other (stated, no rule matched) |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | withdrawn | Jan 6, 2022 | Flame Biosciences | Sponsor Decision | Sponsor / business decision |
| NCT01445327 | Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With… | — | terminated | Oct 3, 2011 | National Cancer Institute (NCI) | Slow, insufficient accrual. | Enrollment / accrual |
| NCT04105062 | LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery | Phase 1 / Phase 2 | withdrawn | Sep 26, 2019 | Washington University School of Medicine | One of the investigators is leaving the University. | Other (stated, no rule matched) |
| NCT03342417 | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | Phase 2 | terminated | Nov 17, 2017 | ExcellaBio LLC | Slow patient accrual | Enrollment / accrual |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | N/A | withdrawn | Aug 11, 2021 | Fujian Cancer Hospital | We could not get the IRB approval. | Other (stated, no rule matched) |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT02908451 | A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer | Phase 1 | terminated | Sep 21, 2016 | AbGenomics B.V Taiwan Branch | COVID-19 pandemic has caused a huge operational difficulty for this ongoing clinical trial, as many… | COVID-19 / pandemic |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03025152 | Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Radical… | N/A | terminated | Jan 19, 2017 | Jiangxi University of Traditional Chinese Medicine | High attrition rate up to 37.7% at one year's follow-up | Other (stated, no rule matched) |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal… | Phase 1 / Phase 2 | terminated | Jul 9, 2003 | National Cancer Institute (NCI) | Discontinued development of G3139 (oblimersen) | Other (stated, no rule matched) |
| NCT01702558 | A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants…(TRAXHER2) | Phase 2 | terminated | Oct 8, 2012 | Hoffmann-La Roche | The sponsor decided to terminate study after 70% of participants had experienced a progression-free… | Sponsor / business decision |
| NCT02862535 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in… | Phase 1 | terminated | Aug 11, 2016 | Gilead Sciences | Study was terminated due to sponsor's decision to not pursue further development of andecaliximab… | Sponsor / business decision |
| NCT02788214 | Helicobacter Pylori Genome Project (HpGP) | — | terminated | Jun 2, 2016 | National Cancer Institute (NCI) | research determined not to be human subject research | Other (stated, no rule matched) |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in… | — | withdrawn | Jun 20, 2018 | University of Southern California | Zero accrual | Enrollment / accrual |
| NCT01402401 | Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2… | Phase 2 | terminated | Jul 26, 2011 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT03554395 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced… | Phase 2 | withdrawn | Jun 13, 2018 | Fuda Cancer Hospital, Guangzhou | No participants enrolled | Enrollment / accrual |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in… | Phase 1 | terminated | Jan 27, 2015 | Famewave Ltd. | not stated | Not stated |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | Phase 1 | terminated | Apr 27, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT03890198 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and… | Early Phase 1 | terminated | Mar 26, 2019 | First Affiliated Hospital Xi'an Jiaotong University | the Preliminary data, progress of this study and the adjustment of the pipeline and strategy . | Sponsor / business decision |
| NCT03704077 | An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various… | Phase 2 | withdrawn | Oct 12, 2018 | Bristol-Myers Squibb | Replaced it with another clinical trial | Other (stated, no rule matched) |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal… | Phase 1 / Phase 2 | withdrawn | Nov 14, 2018 | University of Southern California | PI left | Investigator |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | Phase 1 / Phase 2 | withdrawn | Mar 21, 2016 | Zhi Yang | Reform CAR structure due to safety consideration | Safety / toxicity |
| NCT03644459 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | Phase 1 | withdrawn | Aug 23, 2018 | Lynkcell Inc. | Unable to recruit individuals for the study | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 1, 2023source: clinicaltrials